NCT05177068进行中（未招募）2 期
A Phase II Clinical Study of Fruquintinib Combined With Sintilimab and SOX as Conversion Therapy of Potentially Resectable Stage IV Gastric Cancer
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 42
- 试验地点
- 1
- 主要终点
- Surgical complete resection rate (R0)
研究概览
简要总结
This is a phase II study to evaluate the efficacy and safety of combination of fruquintinib (VEGFR 1/2/3 inhibitor), sintilimab (PD-1 inhibitor) and SOX conversion therapy in unresectable advanced gastric cancer patients.
详细描述
Eligible patients will be given 3 or 6 cycles of combined therapy of fruquintinib + sintilimab + SOX. Then the patients evaluated resectable will be given one additional cycle of combined treatment with sintilimab + SOX, followed by R0 resection. If evaluated unresectable after 6 cycles of combination therapy, the patient will be given palliative first-line treatment. Adjuvant treatment with SOX regimen will be started 4 weeks after R0 resection for a total of 8 cycles in the perioperative period.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed the Informed Consent Form
- •Ages: 18-75 Years (concluding 18 and 75 Years)
- •Pathologically confirmed gastric/gastroesophageal junction adenocarcinoma, and meets one of the following conditions: invasion of adjacent organs such as colon, tail of pancreas and spleen; localized peritoneal metastasis; positive exfoliative cytology of ascites; class I, class II, part of class III and very few class IV stage IV gastric adenocarcinoma according to biological behavior; N3; extensive or fused lymph node metastasis; Krukenberg tumor; Liver metastasis limited to one lobe, less than 5cm in diameter, isolated abdominal aortic metastasis, etc;
- •Untreated(e.g. radiotherapy, chemotherapy, target therapy and immunotherapy)
- •Life expectancy greater than 3 months
- •ECOG(Eastern Cooperative Oncology Group) :0~1
- •Sufficient organ and bone marrow functions as follows:
- •Absolute Neutrophil Count (ANC) ≥1.5×109/L, White Blood Cell≥3.5×109/L;
- •Platelet Count of ≥100×109/L;
- •Hemoglobin≥90g/L;
- •Total Bilirubin (TBIL) ≤1.5 x ULN;
- •ALT and AST<2.5 x ULN, GPT≤1.5×ULN; If there is liver metastasis, then ALT and AST<5.0 x ULN, GPT≤3.0×ULN;
- •Serum Creatinine (SCr) ≤1.0×ULN;
- •Endogenous creatinine clearance rate > 60ml / min (Cockcroft Gault formula);
- •No severe dysfunction of heart, lung and liver; No jaundice and gastrointestinal obstruction; No acute infection
- •Not participating in other clinical trials 4 weeks before and during the treatment
排除标准
- •Known HER-2 positive
- •Distal metastasis to lung, brain, and bone
- •Have received operation on the stomach
- •A history of other malignancies within 5 years prior to inclusion, except for cervical carcinoma in situ, basal or squamous cell skin cancer
- •Patients with any active autoimmune disease or a documented history of autoimmune disease within 4 weeks prior to enrollment
- •Previously received allogeneic bone marrow transplantation or organ transplantation
- •Known hypersensitivity to any of the study drugs or excipients
- •Hypertension that is not controlled by the drug, and is defined as: SBP ≥150 mmHg and/or DBP ≥90 mmHg
- •International normalized ratio (INR) > 1.5 or partially activated prothrombin time (APTT) > 1.5 × ULN
- •Poorly controlled diabetes before enrollment
- •Clinically significant electrolyte abnormalities judged by researchers
- •With any diseases or conditions that affected drug absorption, or the patient could not take drugs orally
- •Patients with obvious evidence of bleeding tendency or medical history within 3 months before enrollment, hemoptysis or thromboembolism within 12 months
- •Cardiovascular diseases with significant clinical significance, including but not limited to acute myocardial infarction, severe / unstable angina pectoris or coronary artery bypass grafting within 6 months before enrollment; Congestive heart failure, New York Heart Association (NYHA) grade > 2; ventricular arrhythmia requiring drug treatment; LVEF (left ventricular ejection fraction) < 50%
- •Active infection or serious infection that is not controlled by drug (≥CTCAE v5.0 Grade 2）
- •History of clinically significant hepatic disease, including, but not limited to, known hepatitis B virus (HBV) infection with HBV DNA positive (copies ≥1×104/ml); known hepatitis C virus infection with HCV RNA positive (copies ≥1×103/m)
- •Women who are pregnant or lactating
- •Urinary protein ≥ ++, and the 24-hour urine protein quantification is greater than 1.0 g
- •Have any other disease, metabolic disorder, physical examination anomaly, abnormal laboratory result, or any other conditions which, according to judgement of the investigator, renders the patient inappropriate for using of the investigational product or may affect interpretation of study results
- •Patients considered unsuitable for inclusion in this study by the investigator.
研究组 & 干预措施
Experimental
Experimental
fruquintinib + sintilimab + SOX (S-1 + oxaliplatin)
干预措施: fruquintinib + sintilimab + SOX (Drug)
结局指标
主要结局
Surgical complete resection rate (R0)
时间窗: about 3 years
This is a complete macroscopic resection of the gross tumor with negative surgical margins
次要结局
- Rate of downstaging(about 3 years)
- Pathological complete response (pCR) rate(about 3 years)
- Major pathological response (MPR)(about 3 years)
- Objective Response Rate (ORR)(about 3 years)
- Event-free survival (EFS)(about 3 years)
- Overall survival (OS)(about 3 years)
- adverse event (AEs)(about 3 years)
- R0 Surgical Conversion Rate(about 3 years)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal CancerMetastatic Colorectal CancerNCT05016869Chinese Academy of Medical Sciences48
招募中
不适用
Fruquintinib Combined With TAS102 for Advanced Gastric CancerGastric CancerNCT06102785Tianjin Medical University Cancer Institute and Hospital30
招募中
2 期
Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRTRectal CancerNCT05763927West China Hospital44
Unknown
2 期
The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer PatientsPancreatic CancerNCT05168527Fudan University30
进行中（未招募）
2 期
Fruquintinib Plus Serplulimab as First-Line Therapy for Metastatic Non-Clear Cell Renal Cell CarcinomaNon-clear Renal Cell CarcinomaNon-clear Cell Renal Cell CarcinomaNCT05831891RenJi Hospital40